Owners, management and financials
CVR: 25950941
Secondary names: CMO BIOTECH A/S, CRO BIOTECH A/S, DOWNSTREAM TECHNOLOGY A/S
Previous names: CMC BIOTECH A/S, CMC BIOPHARMACEUTICALS A/S, CMC BIOLOGICS A/S
DKK 1,959,639,000
Revenue
Net result: DKK -328,010,000
Asahi Glass Co., Ltd. (100%)
CVR · view owners
Kasper Møller
Board: Tadashi Murano (chair) and 4 members
CVR · view management
Active
Founded 15 March 2001
CVR · view overview
1,294 employees
CVR · 2026
Director registered: Kasper Møller
CVR · 01/04/2025
View the full event history
AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,294 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.
Source: annual report 2025, Danish Business Authority
AGC Biologics A/S is currently facing financial challenges, with a significant decline in profitability over the past two years, reporting a loss of 328 million DKK in 2025, following a loss of 115 million DKK in 2024. Revenue has been on a downward trajectory, decreasing from 2.5 billion DKK in 2022 to nearly 2 billion DKK in 2025. Despite a strong equity position of 312 million DKK in 2025, the company's declining profit margins raise concerns about its operational efficiency and sustainability. As a player in the pharmaceutical manufacturing industry, AGC Biologics must address these financial issues to maintain its competitive position.
AI-generated summary · Generated 30/06/2026
Selskabets formål er at drive virksomhed, som omfatter proces- og teknologiudvikling, kontraktproduktion, konsulent- og andre serviceydelser indenfor det bioteknologiske område samt forskning, udvikling og fremstilling af medicinalprodukter, og dermed forbunden virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 2 mia. | -328 mio. | 4.1 mia. | 312 mio. | 1138 | |
| 202401/01/2024 – 31/12/2024 | 2 mia. | -115 mio. | 3.8 mia. | 640 mio. | 1019 | |
| 202301/01/2023 – 31/12/2023 | 2.1 mia. | 243.9 mio. | 3.6 mia. | 307.4 mio. | 956 | |
| 202201/01/2022 – 31/12/2022 | 2.5 mia. | 598.9 mio. | 3.4 mia. | 661.3 mio. | 894 | |
| 202101/01/2021 – 31/12/2021 | 2.2 mia. | 571.7 mio. | 3.1 mia. | 633.6 mio. | 730 | |
| 202001/01/2020 – 31/12/2020 | 1.5 mia. | 278.5 mio. | 2.3 mia. | 339.7 mio. | 441 | |
| 201901/01/2019 – 31/12/2019 | 996.1 mio. | 154.3 mio. | 1.2 mia. | 215.1 mio. | 377 | |
| 201801/01/2018 – 31/12/2018 | 692.6 mio. | 96.2 mio. | 634.6 mio. | 316.8 mio. | 312 | |
| 201701/01/2017 – 31/12/2017 | 643.6 mio. | 74.5 mio. | 501.6 mio. | 290.6 mio. | 303 | |
| 201601/01/2016 – 31/12/2016 | 521.8 mio. | 68.2 mio. | 581 mio. | 216.1 mio. | 245 | |
| 201501/01/2015 – 31/12/2015 | 320.5 mio. | 8.4 mio. | 404.2 mio. | 147.9 mio. | 209 | |
| 201401/01/2014 – 31/12/2014 | 311.1 mio. | 3.2 mio. | 346.6 mio. | 139.5 mio. | 199 | |
| 201301/01/2013 – 31/12/2013 | - | -128 t. | 311.3 mio. | 136.3 mio. | 185 |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
2 properties
Upgrade to Pro to see addresses, building data and ownership details
Property report (PDF)
The entire property portfolio in one report: areas, usage, energy labels, flood exposure, planning zone and local plans.
See an example report (PDF)Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of AGC Biologics A/S is 25950941.
AGC Biologics A/S is owned by Asahi Glass Co., Ltd..
The management of AGC Biologics A/S consists of Kasper Møller.
The board of AGC Biologics A/S consists of Tadashi Murano, Alberto Santagostino and Kasper Møller, with Tadashi Murano as chair.
In 2025, AGC Biologics A/S reported revenue of DKK 1,959,639,000.
AGC Biologics A/S had 1,294 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
AGC Biologics A/S has published its annual report for 2025. Revenue came to DKK 1,959,639,000, and the net result was DKK -328,010,000.
Contact info changed: new phone: 70209470 (June 23, 2026).
Contact info changed: new phone: 70209470 (April 29, 2026).
Contact info changed: new phone: 70209470 (January 22, 2026).
As of January 9, 2026, Yuichiro Tashiro has joined the board of directors of AGC Biologics A/S.
As of January 9, 2026, Tomoko Miyagawa has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2024. Revenue came to DKK 2,016,194,000, and the net result was DKK -115,005,000.
As of April 1, 2025, Kasper Møller is registered as adm. dir. of AGC Biologics A/S.
As of April 1, 2025, Andrea Celia Porchia has stepped down as adm. dir. of AGC Biologics A/S.
As of March 3, 2025, Alberto Santagostino has joined the board of directors of AGC Biologics A/S.
As of March 3, 2025, Mai Iwaya has joined the board of directors of AGC Biologics A/S.
As of March 3, 2025, Akira Nakamura has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2023. Revenue came to DKK 2,092,565,000, and the net result was DKK 243,869,000.
As of June 30, 2024, Patricio Ezequiel Massera has left the board of directors of AGC Biologics A/S.
As of January 8, 2024, Tadashi Murano has joined the board of directors of AGC Biologics A/S.
As of January 8, 2024, Noriyuki Komuro has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2022. Revenue came to DKK 2,517,996,000, and the net result was DKK 598,949,000.
As of September 1, 2022, Akira Nakamura has joined the board of directors of AGC Biologics A/S.
As of September 1, 2022, Hiroshi Nishimura has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2021. Revenue came to DKK 2,185,033,000, and the net result was DKK 571,735,000.
As of March 4, 2022, Andrea Celia Porchia is registered as adm. dir. of AGC Biologics A/S.
As of March 4, 2022, Kasper Møller has stepped down as director of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2020. Revenue came to DKK 1,455,071,000, and the net result was DKK 278,538,000.
As of April 1, 2021, Tomoko Miyagawa has joined the board of directors of AGC Biologics A/S.
As of March 31, 2021, Hideaki Kan has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2019. Revenue came to DKK 996,136,000, and the net result was DKK 154,328,000.
As of March 4, 2020, Patricio Ezequiel Massera has joined the board of directors of AGC Biologics A/S.
As of December 30, 2019, Ikuo Matsukura has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2018. Revenue came to DKK 692,613,000, and the net result was DKK 96,167,000.
As of February 12, 2019, Hideaki Kan has joined the board of directors of AGC Biologics A/S.
As of January 31, 2019, Hideyuki Kurata has left the board of directors of AGC Biologics A/S.
On November 30, 2018, the company changed its name from CMC BIOLOGICS A/S to AGC Biologics A/S.
As of October 3, 2018, Hideyuki Kurata has joined the board of directors of AGC Biologics A/S.
As of October 3, 2018, Noriyuki Komuro has joined the board of directors of AGC Biologics A/S.
As of October 2, 2018, Hideyuki Kurata has left the board of directors of AGC Biologics A/S.
As of October 2, 2018, Noriyuki Komuro has left the board of directors of AGC Biologics A/S.
As of September 17, 2018, Noriyuki Komuro has joined the board of directors of AGC Biologics A/S.
As of August 31, 2018, Yukiteru Nakashita has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2017. Revenue came to DKK 643,563,000, and the net result was DKK 74,528,000.
As of January 31, 2018, Hiroshi Nishimura has joined the board of directors of AGC Biologics A/S.
As of January 31, 2018, Masahiko Fukamachi has left the board of directors of AGC Biologics A/S.
As of June 30, 2017, Yukiteru Nakashita has joined the board of directors of AGC Biologics A/S.
As of June 30, 2017, Patricio Ezequiel Massera has left the board of directors of AGC Biologics A/S.
As of June 30, 2017, Kasper Møller is registered as director of AGC Biologics A/S.
As of June 30, 2017, Patricio Ezequiel Massera has stepped down as director of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2016. Revenue came to DKK 521,795,000, and the net result was DKK 68,222,000.
As of May 31, 2017, KPMG P/S has been appointed auditor of AGC Biologics A/S.
As of May 31, 2017, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of AGC Biologics A/S.
As of February 1, 2017, Kasper Møller has joined the board of directors of AGC Biologics A/S.
As of February 1, 2017, Hideyuki Kurata has joined the board of directors of AGC Biologics A/S.
As of February 1, 2017, Ikuo Matsukura has joined the board of directors of AGC Biologics A/S.
As of February 1, 2017, Masahiko Fukamachi has joined the board of directors of AGC Biologics A/S.
As of February 1, 2017, Peter Klarskov Vilby has left the board of directors of AGC Biologics A/S.
As of February 1, 2017, Stephen Andrew Lehman has left the board of directors of AGC Biologics A/S.
As of February 1, 2017, is registered as an owner of AGC Biologics A/S with an ownership share of 100%.
As of October 1, 2016, Peter Klarskov Vilby has joined the board of directors of AGC Biologics A/S.
As of October 1, 2016, Jesper Bramming has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2015. Revenue came to DKK 320,466,000, and the net result was DKK 8,373,000.
AGC Biologics A/S has published its annual report for 2014. Revenue came to DKK 311,091,000, and the net result was DKK 3,181,000.
As of June 27, 2014, Jesper Bramming has joined the board of directors of AGC Biologics A/S.
As of June 27, 2014, Mads Aage Laustsen has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2013. Gross profit came to DKK 37,248,000, and the net result was DKK -128,000.
As of January 14, 2014, Mads Aage Laustsen has joined the board of directors of AGC Biologics A/S.
As of January 14, 2014, Patricio Ezequiel Massera has joined the board of directors of AGC Biologics A/S.
As of January 14, 2014, David Kauffmann has left the board of directors of AGC Biologics A/S.
As of January 14, 2014, Claès Johan Robert Glassell has left the board of directors of AGC Biologics A/S.
As of January 14, 2014, Mads Aage Laustsen has stepped down as director of AGC Biologics A/S.
As of January 14, 2014, Claès Johan Robert Glassell has stepped down as director of AGC Biologics A/S.
As of January 14, 2014, Gustavo Fabio Mahler has stepped down as director of AGC Biologics A/S.
As of November 1, 2013, Douglas Robert Sanders has stepped down as director of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2012.
As of December 11, 2012, Patricio Ezequiel Massera is registered as director of AGC Biologics A/S.
As of December 11, 2012, Jens Malta Velling has stepped down as director of AGC Biologics A/S.
As of February 10, 2012, Claes Johan Robert Glassell has joined the board of directors of AGC Biologics A/S.
As of February 10, 2012, Claès Johan Robert Glassell has joined the board of directors of AGC Biologics A/S.
As of February 10, 2012, Mads Aage Laustsen has left the board of directors of AGC Biologics A/S.
As of February 10, 2012, Claes Johan Robert Glassell has left the board of directors of AGC Biologics A/S.
As of February 10, 2012, Mads Aage Laustsen is registered as director of AGC Biologics A/S.
As of February 10, 2012, Jens Malta Velling is registered as director of AGC Biologics A/S.
As of February 10, 2012, Claes Johan Robert Glassell is registered as adm. dir. of AGC Biologics A/S.
As of February 10, 2012, Douglas Robert Sanders is registered as director of AGC Biologics A/S.
As of February 10, 2012, Claès Johan Robert Glassell is registered as director of AGC Biologics A/S.
As of February 10, 2012, Gustavo Fabio Mahler is registered as director of AGC Biologics A/S.
As of February 10, 2012, Claes Johan Robert Glassell has stepped down as adm. dir. of AGC Biologics A/S.
As of December 15, 2011, Christian Henrik Tange has stepped down as director of AGC Biologics A/S.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of AGC Biologics A/S.
As of July 1, 2011, A/S PSE NR. 2857 has stepped down as auditor of AGC Biologics A/S.
As of March 10, 2008, Stephen John Bellis has stepped down as director of AGC Biologics A/S.
As of February 29, 2008, Mads Aage Laustsen has joined the board of directors of AGC Biologics A/S.
As of February 29, 2008, Stephen Andrew Lehman has joined the board of directors of AGC Biologics A/S.
As of February 29, 2008, Thomas Tscherning has left the board of directors of AGC Biologics A/S.
As of February 29, 2008, Morten Boje Munk has left the board of directors of AGC Biologics A/S.
As of February 29, 2008, Jesper Zeuthen has left the board of directors of AGC Biologics A/S.
As of February 29, 2008, Paul Howard Michael Toon has left the board of directors of AGC Biologics A/S.
As of February 29, 2008, Claès Johan Robert Glassell has left the board of directors of AGC Biologics A/S.
As of February 29, 2008, Thomas Léon Yves Marie Balland has left the board of directors of AGC Biologics A/S.
As of February 29, 2008, William John Henry has left the board of directors of AGC Biologics A/S.
On February 29, 2008, the company changed its name from CMC BIOPHARMACEUTICALS A/S to CMC BIOLOGICS A/S.
As of August 3, 2007, Thomas Léon Yves Marie Balland has joined the board of directors of AGC Biologics A/S.
As of August 3, 2007, Thomas Léon Yves Marie Balland has left the board of directors of AGC Biologics A/S.
As of November 30, 2006, Christian Henrik Tange is registered as director of AGC Biologics A/S.
As of November 30, 2006, Stephen John Bellis is registered as director of AGC Biologics A/S.
As of November 30, 2006, Anders Vinther has stepped down as director of AGC Biologics A/S.
As of May 31, 2006, William John Henry has joined the board of directors of AGC Biologics A/S.
As of May 31, 2006, Juha Aimo Koivurinta has left the board of directors of AGC Biologics A/S.
As of December 20, 2005, Thomas Tscherning has joined the board of directors of AGC Biologics A/S.
As of December 20, 2005, Jesper Zeuthen has joined the board of directors of AGC Biologics A/S.
As of December 20, 2005, Björn Carl-Johan Dellgren has left the board of directors of AGC Biologics A/S.
As of December 28, 2004, Paul Howard Michael Toon has joined the board of directors of AGC Biologics A/S.
As of December 28, 2004, Claès Johan Robert Glassell has joined the board of directors of AGC Biologics A/S.
As of December 28, 2004, Thomas Léon Yves Marie Balland has joined the board of directors of AGC Biologics A/S.
As of December 8, 2004, Mette Kirstine Agger has left the board of directors of AGC Biologics A/S.
As of May 14, 2003, A/S PSE NR. 2857 has been appointed auditor of AGC Biologics A/S.
As of May 14, 2003, Gert Fisker Tomczyk has stepped down as auditor of AGC Biologics A/S.
As of December 9, 2002, Lone Fønss Schrøder has stepped down as director of AGC Biologics A/S.
As of October 18, 2002, Lone Fønss Schrøder is registered as director of AGC Biologics A/S.
As of October 18, 2002, Anders Vinther is registered as director of AGC Biologics A/S.
On October 18, 2002, the company changed its name from CMC BIOTECH A/S to CMC BIOPHARMACEUTICALS A/S.
As of May 31, 2002, Morten Boje Munk has joined the board of directors of AGC Biologics A/S.
As of May 31, 2002, Björn Carl-Johan Dellgren has joined the board of directors of AGC Biologics A/S.
As of May 31, 2002, Juha Aimo Koivurinta has joined the board of directors of AGC Biologics A/S.
As of May 31, 2002, David Kauffmann has joined the board of directors of AGC Biologics A/S.
As of May 31, 2002, Frank Harder has left the board of directors of AGC Biologics A/S.
As of March 23, 2001, Frank Harder has joined the board of directors of AGC Biologics A/S.
As of March 23, 2001, Mette Kirstine Agger has joined the board of directors of AGC Biologics A/S.
As of March 23, 2001, Lars Hallgren has left the board of directors of AGC Biologics A/S.
As of March 23, 2001, Mads Aage Laustsen has left the board of directors of AGC Biologics A/S.
As of March 23, 2001, Morten Boje Munk has left the board of directors of AGC Biologics A/S.
As of March 15, 2001, Gert Fisker Tomczyk has been appointed auditor of AGC Biologics A/S.
As of March 15, 2001, Lars Hallgren has joined the board of directors of AGC Biologics A/S.
As of March 15, 2001, Mads Aage Laustsen has joined the board of directors of AGC Biologics A/S.
As of March 15, 2001, Morten Boje Munk has joined the board of directors of AGC Biologics A/S.
AGC Biologics A/S was founded on March 15, 2001.
Companies in the same industry and area
CVR 24256790
CVR 14605185
CVR 40831622
CVR 41598263
CVR 44348845
